Patients with fewer total relapses prior to progression and with fewer relapses from Year 3 up to progression (Table 3) actually converted to secondary progressive multiple sclerosis significantly earlier.
The higher antiproliferative activity of 406-nm GEM-ANPs could be attributed to the S phase arrest during cell cycle progression (Table 2).
Increased expression of RASGRP1 and RasGEF (ARHGEF9) may contribute to Ras-ERK signaling that regulates cyclin expression and thus cell cycle progression (Table 3, network 1).
The ROC analysis demonstrated that FR, weight-adjusted FR, and plasma NGAL could significantly predict AKI progression to stage 3; in contrast, urinary L-FABP and NAG levels could not predict AKI progression (Table 2).
Several functional categories have been shown to be important for carcinogenesis and cancer progression (Table S2).
However, in the same multivariate analysis, the Gleason sum had not independent prognostic value of the biochemical progression (Table 3).
The primary component of focal adhesions, FAK, did not exhibit significant changes in mRNA levels during MOSE progression (Table 2).
Consistent with in vitro proliferation and in vivo tumor growth data, knock-down of BRAF, MEK1/2, and PIK3CA in IPC298 cells did not delay cell cycle progression (Table 1 and Figure 8).
In all these knock-down cells, targeting the expression of these proteins led to an accumulation in G1 or S-phase, leading to delay in G2/M progression (Table 1 and Figure 8).
